164 related articles for article (PubMed ID: 33352047)
41. Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.
Lim EJ; Hong DY; Park JH; Joung YH; Darvin P; Kim SY; Na YM; Hwang TS; Ye SK; Moon ES; Cho BW; Do Park K; Lee HK; Park T; Yang YM
PLoS One; 2012; 7(4):e33361. PubMed ID: 22485142
[TBL] [Abstract][Full Text] [Related]
42. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological Inhibition of CDK8 in Triple-Negative Breast Cancer Cell Line MDA-MB-468 Increases E2F1 Protein, Induces Phosphorylation of STAT3 and Apoptosis.
Spear JM; Lu Z; Russu WA
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291686
[TBL] [Abstract][Full Text] [Related]
44. Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis.
Yang J; Qian S; Cai X; Lu W; Hu C; Sun X; Yang Y; Yu Q; Gao SP; Cao P
Mol Cancer Ther; 2016 Jun; 15(6):1190-200. PubMed ID: 26929249
[TBL] [Abstract][Full Text] [Related]
45. Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors.
Zhang C; Yang L; Yang X; Gao Q; Qu Y; Wu L
Bioorg Chem; 2023 Jul; 136():106541. PubMed ID: 37062104
[TBL] [Abstract][Full Text] [Related]
46. Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.
Yue P; Lopez-Tapia F; Paladino D; Li Y; Chen CH; Namanja AT; Hilliard T; Chen Y; Tius MA; Turkson J
Cancer Res; 2016 Feb; 76(3):652-63. PubMed ID: 26088127
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista.
Shi W; Yan D; Zhao C; Xiao M; Wang Y; Ma H; Liu T; Qin H; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Biochem Biophys Res Commun; 2017 Sep; 491(1):159-165. PubMed ID: 28711499
[TBL] [Abstract][Full Text] [Related]
48. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
[TBL] [Abstract][Full Text] [Related]
49. Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.
Kim YH; Yoon YJ; Lee YJ; Kim CH; Lee S; Choung DH; Han DC; Kwon BM
Bioorg Med Chem Lett; 2018 Aug; 28(14):2566-2572. PubMed ID: 29807795
[TBL] [Abstract][Full Text] [Related]
50. Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide.
Wang X; Wu K; Fang L; Yang X; Zheng N; Du Z; Lu Y; Xie Z; Liu Z; Zuo Z; Ye F
Eur J Med Chem; 2021 Jun; 218():113362. PubMed ID: 33774344
[TBL] [Abstract][Full Text] [Related]
51. Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors.
Guo J; Yu W; Cai G; Zhang W; Li S; Zhu J; Song D; Kong L
Eur J Med Chem; 2018 May; 151():752-764. PubMed ID: 29674294
[TBL] [Abstract][Full Text] [Related]
52. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells.
Liu Y; Liu A; Xu Z; Yu W; Wang H; Li C; Lin J
Apoptosis; 2011 May; 16(5):502-10. PubMed ID: 21311975
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
[TBL] [Abstract][Full Text] [Related]
54. 2-Azetidinones: Synthesis and biological evaluation as potential anti-breast cancer agents.
Geesala R; Gangasani JK; Budde M; Balasubramanian S; Vaidya JR; Das A
Eur J Med Chem; 2016 Nov; 124():544-558. PubMed ID: 27608432
[TBL] [Abstract][Full Text] [Related]
55. Increased STAT1 signaling in endocrine-resistant breast cancer.
Huang R; Faratian D; Sims AH; Wilson D; Thomas JS; Harrison DJ; Langdon SP
PLoS One; 2014; 9(4):e94226. PubMed ID: 24728078
[TBL] [Abstract][Full Text] [Related]
56. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells.
Lis C; Rubner S; Roatsch M; Berg A; Gilcrest T; Fu D; Nguyen E; Schmidt AM; Krautscheid H; Meiler J; Berg T
Sci Rep; 2017 Dec; 7(1):17390. PubMed ID: 29234062
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
Kim YJ; Pyo JS; Jung YS; Kwak JH
Bioorg Med Chem Lett; 2017 Feb; 27(3):607-611. PubMed ID: 27993518
[TBL] [Abstract][Full Text] [Related]
58. Identification of potent small-molecule inhibitors of STAT3 with anti-inflammatory properties in RAW 264.7 macrophages.
Capiralla H; Vingtdeux V; Venkatesh J; Dreses-Werringloer U; Zhao H; Davies P; Marambaud P
FEBS J; 2012 Oct; 279(20):3791-9. PubMed ID: 22909341
[TBL] [Abstract][Full Text] [Related]
59. The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway.
Nourbakhsh M; Farzaneh S; Taghikhani A; Zarghi A; Noori S
Anticancer Agents Med Chem; 2020; 20(7):875-886. PubMed ID: 31893999
[TBL] [Abstract][Full Text] [Related]
60. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]